NCT03576443 (ILIAD) is a Phase 2 clinical trial of Idelalisib in Diffuse Large B Cell Lymphoma, sponsored by Nordic Lymphoma Group.

Who is sponsoring NCT03576443?

NCT03576443 is sponsored by Nordic Lymphoma Group.

What drugs are being tested in NCT03576443?

Interventions in NCT03576443: Idelalisib.

What condition does NCT03576443 study?

NCT03576443 studies Diffuse Large B Cell Lymphoma.

Is NCT03576443 still recruiting?

NCT03576443 is currently completed. Last updated 13 October 2021.

Last reviewed 2021-10-13 · How we verify

NCT03576443: ILIAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma

Completed Phase 2 Last updated 13 October 2021

What this trial tests

Phase 2 trial testing Idelalisib in Diffuse Large B Cell Lymphoma in 36 participants. Completed in 30 September 2021.

Timeline

7 July 2017

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Nordic Lymphoma Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	7 July 2017
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	6 locations across Denmark, Sweden

Drugs / interventions tested

Idelalisib — full drug profile →

Conditions studied

Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →

Sponsor

Nordic Lymphoma Group — full company profile →

Who can join

19 and older, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on the high response rate in heavily pretreated patients with indolent B-cell lymphomas, among which it is likely that many have undetected transformed disease, the investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly of the GCB subtype. Possibly, the efficacy may be related to the presence of specific mutations within the B-cell receptor pathway.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
New agents and regimens for diffuse large B cell lymphoma.
Wang L, Li LR, Young KH. · · 2020 · cited 109× · PMID 33317571 · DOI 10.1186/s13045-020-01011-z
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.
Berendsen MR, Stevens WBC, van den Brand M, van Krieken JH, et al · · 2020 · cited 27× · PMID 33260693 · DOI 10.3390/cancers12123553
Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y, Che J, Wu M, Guo Y, et al · · 2022 · cited 26× · PMID 35303910 · DOI 10.1186/s13045-022-01249-9
Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy.
de Jonge AV, Mutis T, Roemer MGM, Scheijen B, et al · · 2020 · cited 15× · PMID 33092116 · DOI 10.3390/cancers12103052
Single cell biomass tracking allows identification and isolation of rare targeted therapy-resistant DLBCL cells within a mixed population.
Murray GF, Guest D, Mikheykin A, Toor A, et al · · 2021 · cited 5× · PMID 33426547 · DOI 10.1039/d0an01769h

Verify or expand the search:

Other trials of Idelalisib

Trials testing the same drug.

NCT06846671 — A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lympho · Phase 3 · recruiting
NCT06205290 — A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Partici · Phase 3 · withdrawn
NCT05725200 — Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT04699461 — Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or R · Phase 2 · terminated
NCT03878524 — Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · Phase 1 · terminated

Other recruiting trials for Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting

Other Nordic Lymphoma Group trials

Trials by the same sponsor.

NCT06755619 — CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01) · recruiting
NCT04332822 — A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in · Phase 3 · recruiting
NCT03505944 — Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma · Phase 1, PHASE2 · unknown
NCT03293173 — Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03576443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nordic Lymphoma Group
Last refreshed: 13 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03576443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing